公开(公告)号：US20220177461A1

公开(公告)日：2022-06-09

申请号：US17678793

申请日：2022-02-23

Applicant: Cornell University

Inventor： John W. Babich ,  Justin WILSON ,  Nikki THIELE ,  James KELLY ,  Shashikanth PONNALA

IPC: C07D413/14 ,  A61K51/04 ,  A61K51/10

Abstract: The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

公开(公告)号：US20210221715A1

公开(公告)日：2021-07-22

申请号：US15734061

申请日：2019-05-31

Applicant: CORNELL UNIVERSITY

Inventor： Justin WILSON ,  Nikki THIELE

IPC: C02F1/68 ,  C07F9/6533 ,  C07D413/14 ,  C02F5/14 ,  C02F5/12

Abstract: Metal-chelating compositions having the structure (1a) wherein: R1, R2, R3, and R4 are independently selected from the following groups: (i) hydrogen atom, (ii) hydrocarbon groups (R) containing 1-12 carbon atoms; (iii) halogen atoms; (iv) —P(R5)(═O)OH groups; (v) —C(═O)OH groups; (vi) —S(═O)2OH groups; and (vii) —OH groups, wherein R5 is selected from hydrocarbon groups (R) and —OH; R1 and R2 may optionally interconnect to form Ring A fused to the ring on which R1 and R2 are present; R3 and R4 may optionally interconnect to form Ring B fused to the ring on which R3 and R4 are present; wherein Ring A and Ring B are optionally and independently substituted with one or more of groups (ii)-(vii). Methods of using the above-described compositions for chelating metal ions having an atomic number of at least 56 (e.g., Ba or Ra) are also described.

公开(公告)号：US20210085808A1

公开(公告)日：2021-03-25

申请号：US16499070

申请日：2018-03-30

Applicant: CORNELL UNIVERSITY

Inventor： Justin WILSON ,  Nikki THIELE

IPC: A61K51/04 ,  A61K51/10

Abstract: The present technology provides compounds as well as compositions including such compounds useful for the treatment of cancers where the compounds are represented by the following formula (I) or a pharmaceutically acceptable salt thereof, wherein M is an alpha-emitting radionuclide.

公开(公告)号：US20180346499A1

公开(公告)日：2018-12-06

申请号：US15778213

申请日：2016-11-02

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  CORNELL UNIVERSITY

Inventor： Kathleen M. GIACOMINI ,  Swati MORE ,  Sook Wah YEE ,  Ethan GEIER ,  Justin WILSON

IPC: C07F15/00 ,  A61K33/24 ,  A61P35/04

CPC classification number: C07F15/0093 ,  A61K33/24 ,  A61P35/04 ,  C07D487/04

Abstract: Disclosed herein, inter alia, are platinum-based compounds useful for treating cancer.

公开(公告)号：US20250163040A1

公开(公告)日：2025-05-22

申请号：US18779607

申请日：2024-07-22

Applicant: Cornell University

Inventor： John W. BABICH ,  Justin WILSON ,  Nikki THIELE ,  James KELLY ,  Shashikanth PONNALA

IPC: C07D413/14 ,  A61K45/06 ,  A61K51/04 ,  A61K51/10 ,  C07B59/00

Abstract: The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

公开(公告)号：US20190175645A1

公开(公告)日：2019-06-13

申请号：US16311961

申请日：2017-06-23

Applicant: CORNELL UNIVERSITY

Inventor： Justin WILSON ,  Kevin KNOPF ,  Sierra MARKER

IPC: A61K33/24 ,  A61P35/00

Abstract: A composition comprising the following structure: (formula I) wherein Re represents a rhenium ion having a +1 charge; (formula II) represents an uncharged bidentate bicyclic ligand bonded to the rhenium (Re) by two ring nitrogen (N) atoms; and L is a neutral ligand independently selected from CO and neutral phosphine molecules, wherein at least one of the L groups is a CO molecule; and X− represents a non-coordinating monovalent anion; wherein (formula II) is unsubstituted or substituted on any of its two rings, and said neutral phosphine molecule may or may not contain a phosphorus atom as a ring phosphorus atom; provided that, if (formula II) is unsubstituted, then one or two of said L groups are selected from said neutral phosphine molecules, with the provision that at least one of the neutral phosphine molecules has a phosphorus atom as a ring phosphorus atom. Methods for treating cancer by administering the above complex are also disclosed.

公开(公告)号：US20230372550A1

公开(公告)日：2023-11-23

申请号：US18084480

申请日：2022-12-19

Applicant: CORNELL UNIVERSITY

Inventor： Justin WILSON ,  Nikki Thiele

IPC: A61K51/04 ,  A61K51/10

CPC classification number: A61K51/0482 ,  A61K51/1051 ,  A61K2121/00 ,  A61K51/1096 ,  A61P35/00

Abstract: The present technology provides compounds as well as compositions including such compounds useful for the treatment of cancers where the compounds are represented by the following formula




or a pharmaceutically acceptable salt thereof, wherein M is an alpha-emitting radionuclide.

公开(公告)号：US20220152228A1

公开(公告)日：2022-05-19

申请号：US17432733

申请日：2020-03-01

Applicant: Washington University ,  Cornell University

Inventor： Daniel THOREK ,  Diane ABOU ,  Justin WILSON ,  Nikki THIELE

IPC: A61K51/04 ,  A61K51/08 ,  A61K51/10 ,  A61K31/415 ,  A61K31/4965 ,  A61K31/18 ,  A61K31/496 ,  A61K31/196 ,  A61K31/4725 ,  A61K31/235 ,  A61K31/4166 ,  A61K31/4422 ,  A61K31/365 ,  A61P39/04 ,  A61P35/00

Abstract: Among the various aspects of the present disclosure is the provision of compositions of isotope-ligand complexes, methods of use thereof, and methods of chelating isotopes. The present disclosure also provides for methods for modulating ion channel transportation of radiopharmaceuticals. For example, the inhibition of radiopharmaceutical transport comprises administering an ion channel transport modulating or inhibiting agent (e.g., a calcium channel inhibitor) in an amount effective to inhibit gastrointestinal uptake.

公开(公告)号：US20220016277A1

公开(公告)日：2022-01-20

申请号：US17294375

申请日：2019-11-20

Applicant: Cornell University

Inventor： John W. Babich ,  Justin WILSON ,  Nikki THIELE ,  James M. Kelly ,  Shashikanth Ponnala

IPC: A61K51/10 ,  C07D413/14 ,  A61K51/04

Abstract: The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following Formulas (I), or a pharmaceutically acceptable salt thereof (IA), or a pharmaceutically acceptable salt thereof (II), or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.